AVTX

Avalo Therapeutics (AVTX)

About Avalo Therapeutics (AVTX)

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.

Details

Daily high
$9.80
Daily low
$8.72
Price at open
$9.10
52 Week High
$34.46
52 Week Low
$3.95
Market cap
93.2M
Dividend yield
0.00%
Volume
949,861
Avg. volume
142,733
P/E ratio
-.05

Avalo Therapeutics News

Details

Daily high
$9.80
Daily low
$8.72
Price at open
$9.10
52 Week High
$34.46
52 Week Low
$3.95
Market cap
93.2M
Dividend yield
0.00%
Volume
949,861
Avg. volume
142,733
P/E ratio
-.05